LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
+0.48%0
Insider buys (3m)
7
Insider sells (3m)
-$299.8K
Net value (3m)
-17.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | Sale | 1,304 | $4.96 |
| Aug 19, 2026 | Tamayo Louis Edward · officer: Chief Financial Officer | Sale | 4,117 | $4.91 |
| Aug 19, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | Sale | 3,345 | $4.95 |
| Jul 1, 2026 | Tamayo Louis Edward · officer: Chief Financial Officer | Sale | 4,641 | $4.49 |
| Jul 1, 2026 | Tamayo Louis Edward · officer: Chief Financial Officer | A-Award | 12,000 | $0.00 |
| Jul 1, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | Sale | 25,947 | $4.48 |
| Jul 1, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | A-Award | 12,060 | $0.00 |
| Jul 1, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | Sale | 4,666 | $4.48 |
| Jul 1, 2026 | Bhalla Narinder Pal · officer: Chief Medical Officer | A-Award | 55,000 | $0.00 |
| Jul 1, 2026 | Bhalla Narinder Pal · officer: Chief Medical Officer | Sale | 22,306 | $4.42 |
| Jul 1, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | A-Award | 67,000 | $0.00 |
| Jun 29, 2026 | DIAZ REINALDO M · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | Tanguler Tolga · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | Van Hauwermeiren Timothy · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | CHOLMONDELEY PAULA H · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | Altschuler Steven · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | COOPERSTONE BRENDA · director | A-Award | 35,000 | $4.70 |
| Jun 29, 2026 | Agger Mette Kirstine · director | A-Award | 35,000 | $4.70 |
| May 20, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | Sale | 1,302 | $5.07 |
| May 20, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | Sale | 3,342 | $5.06 |
| Apr 30, 2026 | Sepp-Lorenzino Laura · director | A-Award | 50,000 | $5.81 |
| Apr 7, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | Sale | 55,000 | $5.69 |
| Mar 17, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | A-Award | 5,930 | $2.64 |
| Mar 17, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | A-Award | 2,623 | $2.64 |
| Feb 20, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | Sale | 721 | $9.27 |
| Feb 20, 2026 | Otero Jose Manuel · officer: Chief Operating Officer | Sale | 3,016 | $6.40 |
| Feb 20, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | Sale | 10,173 | $6.38 |
| Feb 17, 2026 | Bhalla Narinder Pal · officer: Chief Medical Officer | A-Award | 49,500 | $0.00 |
| Feb 17, 2026 | Bhalla Narinder Pal · officer: Chief Medical Officer | A-Award | 297,000 | $6.31 |
| Feb 6, 2026 | Townsend Richard Nolan · director, officer: Chief Executive Officer | A-Award | 646,665 | $7.27 |
Institutional positioning
13F filings over the trailing two quarters
New 49Increased 117Reduced 82Sold out 21
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | Increased | 6,384,200 | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 6,184,134 | May 15, 2026 |
| Affinity Asset Advisors, LLC | Increased | 5,807,611 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 5,739,455 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 5,110,871 | May 13, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 5,050,211 | May 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 5,000,000 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 5,000,000 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 4,976,429 | May 18, 2026 |
| Frazier Life Sciences Management, L.P. | Increased | 4,824,725 | Aug 14, 2026 |
| VESTAL POINT CAPITAL, LP | Unchanged | 4,475,000 | May 15, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4,424,725 | May 15, 2026 |
| STATE STREET CORP | Increased | 4,354,757 | Aug 7, 2026 |
| Vestal Point Capital, LP | Reduced | 4,320,000 | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | Reduced | 4,175,382 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 19, 2026